TD Cowen analyst Tyler Van Buren has maintained their bullish stance on SMMT stock, giving a Buy rating today.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Tyler Van Buren’s rating is based on several considerations following Summit Therapeutics’ recent earnings report. The adjustments in expense estimates reflect the company’s ongoing Phase III trials and the expected start of the Phase III HARMONi-GI3 trial, indicating a strategic focus on advancing their clinical pipeline.
These developments suggest a positive outlook for Summit Therapeutics, as the company is actively investing in its growth and future potential. The Buy rating reflects confidence in the company’s ability to execute its clinical strategies and achieve favorable outcomes in its trials.
Van Buren covers the Healthcare sector, focusing on stocks such as Soleno Therapeutics, Gilead Sciences, and Summit Therapeutics. According to TipRanks, Van Buren has an average return of 8.2% and a 50.52% success rate on recommended stocks.